Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409305 · ClinicalTrials.gov registry record · Phase 2
The Effect of Betahistine on Body Weight in Obese Subjects
A Phase 2 study of Obesity, sponsored by OBEcure.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 19
- Study locations
NCT00409305: Completed Phase 2 study of Obesity, sponsored by OBEcure.
NCT00409305 is a Phase 2 study of Obesity that has completed, run by OBEcure. The registered enrollment target is 280 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (66% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00409305, a Phase 2 study of Obesity, has completed, sponsored by OBEcure.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to examine the effect that betahistine has on body weight in obese subjects.
Conditions Studied
Interventions
- BEHAVIORAL Dietary counseling
- DRUG Betahistine
Study Locations (19)
California
- Scripps Clinic, Nutrition Metabolic Research - San Diego
- Diablo Clinical Research, Inc. - Walnut Creek
Illinois
- Radiant Research, Inc. - Chicago
- NCCR - Chicago
Indiana
- American Health Network - Indianapolis
- Midwest Institute for Clinical Research - Indianapolis
New York
- Comprehensive Weight Control Program - New York
- Rochester Clinical Research, Inc. - Rochester
Alabama
- Cahaba Research, Inc. - Birmingham
Florida
- Miami Research Associates, Inc., Nutrition Division - Miami
Georgia
- CSRA Partners in Health, Inc. - Augusta
Kansas
- Radiant Research, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00409305
The ClinicalTrials.gov registry entry for NCT00409305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (66% lower). The listed sponsor is OBEcure, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Dietary counseling is the first listed.
NCT00409305 reports 19 study locations spanning 15 distinct geographic areas - top geographies include California, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT00409305 about?
NCT00409305 is a clinical study titled "The Effect of Betahistine on Body Weight in Obese Subjects". The purpose of this study is to examine the effect that betahistine has on body weight in obese subjects.
What is the current status of trial NCT00409305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2007-01. Estimated completion is 2007-06.
What conditions does trial NCT00409305 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT00409305?
The interventions under investigation include: Dietary counseling (BEHAVIORAL), Betahistine (DRUG).
Who is sponsoring clinical trial NCT00409305?
This trial is sponsored by OBEcure, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00409305 being conducted?
This trial has 19 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.